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Abstract
Background:  In the present study, we examined clinical and laser-evoked potentials (LEP)
features in two groups of chronic tension-type headache (CTTH) patients treated with two
different approaches: intra-oral appliance of prosthesis, aiming to reduce muscular tenderness, and
10 mg daily amitriptyline.
Methods: Eighteen patients with diagnosed CTTH participated in this open label, controlled study.
A baseline evaluation was performed for clinical features, Total Tenderness Score (TTS) and a
topographic analysis of LEPs obtained manually and the pericranial points stimulation in all patients
vs. healthy subjects. Thereafter, patients were randomly assigned to a two-month treatment by
either amitriptyline or intra-oral appliance.
Results and discussion: Both the intra-oral appliance and amitriptyline significantly reduced
headache frequency. The TTS was significantly reduced in the group treated with the appliance. The
amplitude of P2 response elicited by stimulation of pericranial zones showed a reduction after
amitriptyline treatment.
Both therapies were effective in reducing headache severity, the appliance with a prevalent action
on the pericranial muscular tenderness, amitriptyline reducing the activity of the central cortical
structures subtending pain elaboration
Conclusion: The results of this study may suggest that in CTTH both the interventions at the
peripheral and central levels improve the outcome of headache.
Introduction
Although tension-type headache is the most common
type of primary headache, its pathophysiology is poorly
understood. The best documented abnormality in
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patients with tension type headache is increased pericra-
nial myofascial tenderness [1,2]. Pericranial tenderness
has been shown to be positively associated with both the
intensity and the frequency of tension type headache
[2,3]. It is generally accepted that myofascial tenderness
probably plays a key role in the pathophysiology of ten-
sion type headache. Recently, a pathophysiological model
for tension type headache has been proposed. Accord-
ingly, the main problem is central sensitization at the level
of the spinal dorsal horn/trigeminal nucleus, resulting
from prolonged nociceptive inputs from pericranial myo-
fascial tissues. This central sensitization is posited to cause
supraspinal sensitization and central neuroplastic
changes, that possibly lead to increased pericranial muscle
activity [4].
In a recent study we examined features of Laser evoked
potentials (LEPs) [5,6], as well as cutaneous heat-pain
thresholds to laser stimulation, in relation to the tender-
ness of pericranial muscles in chronic tension type head-
ache (CTTH), during a pain-free phase [7]. The amplitude
of the N2-P2 complex elicited by stimulation of the
pericranial zone was greater in CTTH patients than in con-
trols; the amplitude increase was significantly associated
with the Total Tenderness Score (TTS) [8]. Our findings
suggested that pericranial tenderness may be a primary
phenomenon that precedes headache, mediated by
increased pain awareness at the cortical level.
In our previous study, we postulated that a cortical hyper-
vigilance to the pericranial muscles was correlated with
muscle tenderness, which may be aggravated or generated
by a high level of cortical arousal [7]. The role of periph-
eral factors in the induction of a specific hyper-attention
to painful stimuli at pericranial sites, and the efficacy of a
specific intervention at peripheral level in improving the
outcome of headache is presently unclear. Peripheral
nociception at the level of pericranial muscles may be
reduced by specific interventions aiming to reduce the
muscular tenderness. Previously, intra-oral orthoses,
designed to act on the bite, have been shown to be effec-
tive in the treatment of myofascial pain and headache
pain originating in the pericranial muscles [9,10]. In this
study we used an intra-oral non-occluding appliance,
originally designed for the treatment of myofascial pain
and headache related to muscle tension [11].
Amitriptyline is the only established prophylactic treat-
ment of CTTH [12,13] and it has been the drug of choice
for chronic pain since 1964 [14]. Though the mode of
action of amitriptyline is not fully understood, evidence
suggests that it acts at the central level by inhibiting the
neuronal re-uptake of norepinephrine and serotonin in
the brain [12], with an effect quite independent from its
antidepressant action [15].
In a previous study we have described in brief form the
effects of amitryptiline and intra-oral appliance on the
clinical and LEPs features of CTTH patients [16]. The aim
of the present study was to describe in detail the effect of
a specific intervention at the peripheral level consisting of
an intra-oral appliance, compared to the central effect of
amitriptyline, on the LEPs, the TTS and the main clinical
features of two groups of CTTH patients.
Methods
Subjects
Eighteen outpatients attending the Headache Centre of
the Neurology Clinic of Bari University, who fulfilled the
criteria of CTTH associated with a pericranial muscles ten-
derness, according to International Headache Society
(code 2.3.1) [17], participated in the study. All patients
had been attending the practice for at least 6 months, dur-
ing which they had been requested to register all headache
episodes in a diary. All patients underwent a standardized
interview as well as a clinical neurological, psychiatric and
dental examination: they were also examined by Zung's
Self-rating Anxiety Scale (SAS) [18] and Self-rating
Depression Scale [19] (SDS).
The clinical features of the patients are summarized in
Table 1. Subjects with general medical, neurological, psy-
chiatric (according to American Psychiatric Association,
1994) diseases, and patients who were taking psychoac-
tive drugs, prophylactic treatments for headache, or had
displayed over-use of analgesic drugs in the last 2 months,
were excluded. In addition, criteria for exclusion also
included dental malocclusions, existence of any remova-
ble dental appliance, and/or acute oral conditions. All
patients who participated were instructed to attend to the
recording session free from pain and free of medication
intake for at least the previous 12 h. Longer intervals were
not possible, since most of the patients experienced daily
headache (Table 1).
All patients gave their informed consent to the study,
which was ethically approved by the of Neurological and
Psychiatric Science Department of Bari University). The
clinical examination and recording session were carried
out between 12 and 55 hours after the end of the last
headache (mean 23 ± 12.2 hours), in the basal condition.
The TTS was performed by manual palpation by one neu-
rologist with experience in headache, who was experimen-
tally blinded to the assigned treatment. The right frontalis,
masseter, temporalis, pterygoid, sternocleidomastoid,
and trapezius muscles, and the sternocleidomastoid and
neck muscle insertions were examined using the TTS sys-
tem. This method uses a combination of behavioural and
verbal items, each of which is scored on a four-point Lik-
ert scale, defined as: 0 denial of tenderness, no visible
reaction; 1 verbal report of discomfort or mild pain, noHead & Face Medicine 2006, 2:15 http://www.head-face-med.com/content/2/1/15
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visible reaction; 2 verbal report of moderate pain, with or
without visible reaction; 3 verbal report of marked pain
and visible expression of discomfort, according to Langer-
mark and Olesen [20]. The LEP recording was performed
at least 1 h after the TTS examination.
CO2 laser stimulation and LEP recording
Each subject was seated in a comfortable chair positioned
in a quiet room with an ambient temperature of 21–23
°C, in an awake and relaxed state, with eyes closed. Sub-
jects and experimenters wore protective goggles during
data acquisition. The pain stimulus was a laser pulse
(wavelength 10.6 µm) generated by a CO2 laser (Neuro-
las, Electronic Engineering, Florence, Italy; http://
www.elengroup.com). The beam diameter was 2.5 mm
and the duration of the stimulus pulse was 20 ms. Signals
were recorded through 19 disk electrodes, according to
the 10–20 International System (impedance below 5000
ohms), referring to the nasion with the ground at Fpz.
Another electrode was placed above the right eye to record
the electrooculogram (EOG). Signals were amplified, fil-
tered (0.5–80 Hz), and stored on a biopotential analyser
(Micromed System Plus; Micromed, Mogliano Veneto,
Italy; http://www.micromed-it.com). Time analysis was
for 1s, at a sampling rate of 512 Hz. Trials contaminated
by ocular or muscle artefacts were excluded from the anal-
ysis. An automatic artefact rejection system excluded from
the average all runs containing transient signals exceeding
65 mV on any recording channel, including the EOG.
Stimulation
Cutaneous heat stimuli were delivered to the dorsum of
the right hand (RH), and to the skin above the right fron-
talis, masseter, temporalis, sternocleidomastoid, and tra-
pezius muscles, and to the neck muscle insertions. The site
of stimulation was visualized by a laser beam. The loca-
tion of the impact on the skin was adjusted slightly
between two successive stimuli to avoid the sensitization
of the nociceptors and nociceptor fatigue. A 7.5-W laser
intensity with 25 ms duration was used in each case [21].
Subjects were requested to report the quality of sensation
(pain rating :PR) after each stimulus presentation using a
visual analogue scale (VAS) in which 0 indicated no pain
in white, increasing in a gradual scale of reds to 100,
which indicated severe pain. Two series of 20 stimuli were
delivered in each case with an interstimulus interval of 10
s. The order of the stimulation sites was modified ran-
domly across patients and controls.
LEPs analysis
LEP recordings were analyzed by an investigator blind to
the clinical conditions. Blocks of at least 15 trials free from
artefacts were averaged offline. A grand average across the
two series of stimuli was obtained for each patient. LEPs
were identified based on their latency and distribution,
and three responses, N1, N2 and P2, were labelled [22].
Absolute latencies of scalp potentials were measured at
the highest peak of each response component and the
amplitude of each wave was measured from the baseline.
Table 1: Clinical features of chronic tension type headache patients.
Patients Age Sex Age of illness 
(years)
Frequency of headache 
(days with headache/month)
Totale 
Tenderness score
Self-evaluating 
Anxiety Scale (Zung)
Self-evaluating 
Depression Scale (Zung)
15 5 F2 3 0 1 1 3 1 3 2
23 5 M 3 1 5 3 3 0 3 2
35 5 F1 3 0 7 3 5 3 6
43 4 M 3 1 6 3 3 1 3 3
55 4 F2 3 0 7 3 6 3 5
63 4 M 3 1 5 2 2 4 2 5
7 51 F 10 15 11 57 38
84 8 F1 1 5 3 4 0 3 6
93 0 M 2 3 0 4 3 1 2 7
10 34 M 2 30 3 37 33
11 29 F 3 21 4 32 29
12 33 F 2 30 3 36 42
13 35 M 10 20 8 36 34
14 49 M 1 30 5 37 33
15 18 F 5 30 3 35 34
16 46 F 20 16 7 48 39
17 20 M 6 21 3 32 36
18 45 F 12 17 7 45 46
The patients reported in outlined characters, were assigned to amitriptyiline, the remainder to the appliance appliance.Head & Face Medicine 2006, 2:15 http://www.head-face-med.com/content/2/1/15
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The N1 component was measured on the temporal deri-
vation (T3), the P2 and N2 components were analysed at
the vertex (CZ). In addition, each case was evaluated for
the amplitude of N1 referring off-line the contralateral
temporo-parietal derivations to Fz reference : the mean
amplitude values across T5-Fz;T3-Fz;P3-Fz was the tempo-
ral N1. We also computed the amplitude of N2 (vertex
N2) and P2 (vertex P2), computing in each case the mean
value across the vertex and midline derivations (Cz-Fz-Pz,
C3, C4, referred to the nasion).
Experimental procedure
A basal evaluation of clinical features and TTS were per-
formed in all patients. (T0:basal conditions); patients
were then consecutively allocated to the two groups: one
patient was allocated to the amitriptyline group for each
one who entered the intra-oral appliance group (Table 1).
It was an open-label randomised study. Patients assigned
to the drug therapy assumed a dosage of 10 mg amitriptyl-
ine each evening. We used a low dosage of drug, in order
to obtain a therapeutic effect avoiding sedation. In the
other group, an appliance designed to reduce the pericra-
nial tenderness, was fitted. The appliance was fabricated at
"The Headache Clinic" in Johannesburg, on the basis of
their previous experience of its efficacy in treating primary
headache (Fig.1)[11]. The appliance was constructed on
the plaster casts of the selected patients' maxillary teeth:
the devices were fitted to each patient, and adjusted in
order to not interfere with normal speech. The final shape
and thickness of the prostheses was different for each
patient [16], depending on the shape of the tongue and
palate, and the tongue movements during speech.
Patients in this group were instructed to wear the appli-
ance night and day for two consecutive months. Patients
in the amitriptyline group were instructed to take the drug
every evening for two consecutive months, during which
they should observe any side-effect. We joined all patients
weekly by telephonic interview, to test their compliance.
After two months (T1), they were requested to come again
free from pain and analgesic treatment for at least 12
hours. The mean frequency of headache in the last two
months was computed and the TTS and LEPs were per-
formed, according to the methods described above. The
TTS and LEP evaluations were done at least 12 hours after
removal of the appliance or the last amitriptyline intake.
In addition, patients were submitted again to Zung's Self-
rating Anxiety Scale (SAS) [18] and Self-rating Depression
Scale (SDS) [19].
Statistic analysis
The comparison between the two treated groups was per-
formed by the univariate ANOVA, using the conditions T0
and T1 and the type of treatment as factors and the fre-
quency of headache, the TTS, the PR, the temporal N1 and
the vertex N2 and P2 as variables.
Results
Clinical features
No patient reported significant side effects with the appli-
ance: one of them experienced slight speech disturbance
after a month, and the appliance had to be adjusted fur-
ther. Two patients reported drowsiness due to the
amitriptyline, but this did not interfere with their daily
activities, and, therefore, continued with the medication
regimen. All the clinical features were similar in the two
selected groups and ANOVA was employed for treatment
as a factor. Both the oral appliance and amitriptyline sig-
nificantly reduced headache frequency (Fig.2): the two-
way ANOVA with the treatment and the condition as fac-
An example of oral appliance before (upper) and after  (lower) adjustement Figure 1
An example of oral appliance before (upper) and after 
(lower) adjustement.Head & Face Medicine 2006, 2:15 http://www.head-face-med.com/content/2/1/15
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tors, showed a significant effect of the treatment (F = 56.5
p < 0.0001), which was not dissimilar between the two
groups (treatment × condition : F = 0.4 p = 0.53). The TTS
was significantly different between the two groups, for
reduced values in the group treated by the appliance
(ANOVA with treatment as factor F = 17.11 p = 0.0001):
any way, the difference between the two groups
approached the statistical significance when the effect of
the condition was considered (ANOVA with condition ×
treatment as factors: F: 4.36 p = 0.052). (Fig.2) The anxiety
Clinical Features of chronic tension type headache patients Figure 2
Clinical Features of chronic tension type headache patients. Mean values and standard deviations of the main clinical 
features, frequency of headache, Total Tenderness Score (TTS), Self Evaluating Anxiety Scale (SAS) and Self Evaluating Depres-
sion Scale (SDS) in chronic tension type headache in basal conditions (T0) and after two months treatment (T1) by appliance 
(n°9 patients) and amitriptyline (n°9 patients).Head & Face Medicine 2006, 2:15 http://www.head-face-med.com/content/2/1/15
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levels, tested by the Zung scale, were similar in the two
groups (ANOVA with treatment as factor: F = 0.86 p =
0.35), the effect of the condition was not statistically rele-
vant (condition × treatment: F = 0.64;p = 0.42). The
depression levels were reduced in the group treated by
amitriptyline, but the effect of condition × treatment did
not reach statistic significance (condition × treatment :
3.86 p = 0.066). (Fig. 2).
The pain rating of laser stimulus in the two treatments was
not significantly different at any of the stimulated sites.
LEPs
The amitriptyline provoked a reduction of the vertex P2
(Table 2) at the neck point, masseter, and temporal sites
(Fig 3). The oral device did not reduce the amplitude of
LEPs at any stimulated point (Table 2). The mean percent
rate of reduction of the vertex P2 across the whole range
of pericranial sites was 35.4 ± 12.6 in amitriptyline group,
and 9.9 ± 7.8 in the appliance treated group (ANOVA with
cases as factor: F = 25.4 p < 0.001). In the amitriptyline
group, it was correlated with the percentage rate of reduc-
tion of headache frequency (Pearson correlation test:
0.71; p 0.049), but it was not correlated with the mean
percentage reduction of TTS, SAS and SDS.
Discussion
A significant weakness of our study design was the lack of
placebo. This was unavoidable due to the fact that we were
unable to design a "placebo" intra-oral appliance. Instead
we compared two different therapeutic approaches, one
with a prevalent effect at the peripheral and the other at
the central level. This method may be limited, because an
oral device may produce a placebo effect, which acts at the
central level producing an analgesic effect. A recent review
stated that the gold standard of pharmacological research,
the double blind placebo control trial, cannot readily be
emulated in other forms of therapeutic design, as the
behavioral therapy trials [23]: in the case of the appliance,
the design of an intra-oral applicance without any effect
on muscular tenderness, may be supposed for further
evaluations. The appliance was efficient in reducing the
frequency of headache. Its action is probably a result of its
effect on muscle tension, as previously observed [11]. The
group treated with the appliance showed a significant
reduction of pericranial tenderness compared to the
group treated by amitriptyline. The appliance failed to
reduce LEP amplitudes, so the peripheral effect on muscle
contraction seemed to be efficacious despite it did not
reduce the cortical response to experimental painful
pericranial stimulation. If tension type headache patients
showed a tendency toward a self generation of pericranial
Table 2: Laser evoked potential features in chronic tension type headache patients
Neck front. mass ster. temp trap. hand
T0 AMYT n1 temp M -1 -3 -2 0,4 -2 -2,3 -3
uV SD 3,2 5 2,1 3,3 2 5,3 5,3
T 1 M - 1 , 5 - 3 - 3- 1 , 2- 3 , 2- 2 , 4 - 2
S D 26 , 22 , 26 , 6 45 , 44 , 5
T0 PROST. M -3 -2 2,1 -3 -3 -2,3 -2
S D 8 83 , 27 , 1 46 , 53 , 4
T1 M -1 -1 1,4 -3,1 -2,2 -2,1 -1,6
SD 1,9 5,5 4,2 -3,2 3 4,5 4,5
T0 AMYT n2 vert M -12 -16,2 -16,6 5,3 -16,2 -9,8 -16
uV SD 7 14,3 6 7 3,5 6,6 14,3
T1 M -11 -16,3 *-8 -12,3 -8,8 -7 -16,2
SD 10,9 11,7 4 8,9 8,4 7,5 9,8
T0 PROST. M -7,3 -19 12,7 -8 -13 -8,4 -12,3
SD 10,1 15,5 4,6 12 10,2 13,4 4,5
T1 M -15,1 -19,2 10 -12,4 -9,8 -13,5 -10,4
S D 1 1 , 21 1 , 21 0 , 3 9 , 1 9 , 32 0 , 11 0 , 4
T 0 A M Y T p 2  v e r t M 1 6 , 61 4 , 9 2 1 1 82 1 , 41 5 , 71 1 , 3
u V S D 6 1 0 9 , 289 6 , 7 9 , 9
T1 M *11 11,2 *11,3 15,4 *13,5 12,3 14,3
S D 6 1 16 3 , 45 8 , 9 1 0 , 4
T0 PROST. M 15 10 10,8 11,3 13,4 11,2 10,3
S D 9625 1 0 , 3 5 , 5 2 , 4
T1 M 11 11 10,2 11,4 14,5 9,9 10,5
SD 11,1 14 11,3 12 14,3 7,2 2,6
Mean values (M) and standard deviations (SD) of laser evoked potentials (LEPs) amplitude in chronic tension type headache amytriptiline group 
(n°9) and oral appliance group (n°9), computed in basal conditions (T0) and after 2 months treatment (T1). Results of ANOVA with condition as 
factor and LEPs amplitudes as variable within the amytriptiline group. * p < 0.05Head & Face Medicine 2006, 2:15 http://www.head-face-med.com/content/2/1/15
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muscular tenderness by a mechanism of cortical origin
[7], action at the muscular level may improve headache:
the pericranial tenderness generates phenomena of sensi-
tization at peripheral and central levels, which cause the
persistence and the extension of headache, limited by an
intervention at muscular level. The oral appliance was
well tolerated in our series and no patient dropped out
because of serious adverse effects. As in previous studies
[13], amitriptyline was efficacious in reducing headache,
and was well tolerated in all patients. Although statistical
analysis did not show any relevant difference between the
two treatments, the effect of amitriptyline on headache
frequency appeared superior to that of the appliance,
despite the low dosage and the scarce effect on the pericra-
nial tenderness. Though the mode of action of amitriptyl-
ine is not fully known, evidence has shown that it acts at
Laser evoked potentials in chronic tension type headache patients Figure 3
Laser evoked potentials in chronic tension type headache patients. Grand average of LEPs across 9 chronic tension 
type headache patients assigned to amitriptyline and 9 assigned to the oral appliance in basal conditions (T0) and after two 
months treatment (T1). The amitriptyline induced a reduction of the later positive wave, the P2.Head & Face Medicine 2006, 2:15 http://www.head-face-med.com/content/2/1/15
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the central level by inhibiting the neuronal re-uptake of
norepinephrine and serotonin in the brain [12], with an
effect quite independent from its antidepressant action.
As previously reported, [15] depression and anxiety were
not reduced in our patients by amitriptyline, in relation to
clinical efficacy on headache. Amitriptyline reduced the
amplitude of the vertex LEP complex when most of the
pericranial points were stimulated, confirming its inhibit-
ing effect at the level of the pain-modulating cortex. This
reducing effect on LEP amplitude was not linked with the
decline of TTS, which remained high during the headache-
free phase of the amitriptyline-treated group. In previous
studies [7,24] we suggested that TTS is mediated by a cor-
tical hyper-attention to pericranial points and that the
muscular pain should be centrally mediated. In this study
we have observed that amytriptiline reduced the cortical
activation by pericranial painful laser stimuli leaving
quite unmodified the muscular tenderness, accordingly
the appliance reduced TTS without reducing the LEPs. The
tendency toward a self-generation of pericranial pain was
not completely reversed in chronic tension type headache
patients by a therapeutic approach at the peripheral and
central levels, which appeared efficient on headache.
Amitriptyline seemed to act on the central pain modulat-
ing system, specially on the nociceptive cortex which gen-
erates the late P2 wave. The reduced activity of the cortical
zones devoted to the emotive and attentive components
of pain [24], improves the suffering of tension-type head-
ache, even if the pericranial tenderness persists. On the
other hand the reduction of pericranial tenderness
induced by the appliance alleviates headache, despite the
persistence of a high level of cortical activation against
pericranial painful stimuli.
Conclusion
The pericranial tenderness, whose generation, according
to our studies, is favoured by cortical hyper-attention to
pericranial sites [7,14], may initiate a self sustaining cir-
cuit in which prolonged nociceptive input from pericra-
nial myofascial tissues causes central sensitization at the
level of the spinal dorsal horn/trigeminal nucleus, with
supraspinal sensitisation and further activation of cortical
nociceptive areas, which increase the pericranial muscle
activity and the painful afferent stimuli. [4]
The results obtained within the experimental conditions
of the present study indicate that intervention at both the
peripheral and central levels may interrupt this reverberat-
ing circuit, improving the outcome of headache.
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